Clinical Evidence

Investigation of the effect of short-term supplementation with curcuminoids on circulating small dense low-density lipoprotein concentrations in obese dyslipidemic subjects: a randomized double-blind placebo-controlled cross-over trial
ARYA Atheroscler.2014;10(5):280–286. PMID: 25477987
Obesity can lead to various other comorbidities viz., coronary artery disease, hypertension, type 2 diabetes mellitus, respiratory disorders, and dyslipidemia. In dyslipidemia condition there will be altered content and ratio of lipoproteins viz., fasting plasma triglycerides, high LDL cholesterol, low HDL cholesterol, elevated blood glucose, and insulin levels and high blood pressure. Recent advances have identified small dense LDL as metabolic risk factors associated with obesity and dyslipidemia which plays a pivotal role in the induction of comorbidities resulting due to dyslipidemia. Thus, small dense LDL has become one of the markers for dyslipidemia condition and promising target to reduce the comorbidities of dyslipidemia.

To assess changes in serum small dense LDL concentrations following supplementation with curcuminoids.


This study was designed as a randomized double-blind placebo-controlled cross-over trial. 30 obese dyslipidemia subjects were assigned to curcuminoids (1 g/day) or placebo for 4 weeks, followed by a 2-week washout and then treatment with the alternate for another 4 weeks. Serum small dense LDL was measured at baseline and weeks 4, 6, and 10 of the trial.

  • Supplementation with curcuminoids (1 g/day) did not cause any significant alteration in serum small dense LDL (P > 0.05) 

Four-week supplementation with curcuminoids was not associated with any significant alteration in circulating small dense LDL concentrations.